Key facts
- Aminex Therapeutics’s last known valuation is $105.1M (Dec 2025).
- It has raised $47.6M across 6 recorded rounds; the latest was Early Stage VC ($15.1M) in Oct 2022.
- Notable investors include United States Department of the Treasury.
- Aminex Therapeutics has filed 6 Form Ds with the SEC since 2014, most recently Dec 2025 ($15.1M sold to 162 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 6 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Aminex Therapeutics
Funding rounds
6 roundsAbout Aminex Therapeutics
Operator of a drug development company intended to focus on advancing novel immunotherapy for cancer treatment and cure. The company's immuno-oncology approach significantly reduces the uptake and production of polyamines and, in turn, myeloid-derived suppressor cells in the tumor microenvironment, allowing for activation of the innate immune system to attack solid tumors, enabling patients' innate immune systems to attack solid tumors in their bodies.
- Sector
- Healthcare
- HQ
- Kenmore, WA, United States
- Founded
- 2009
- Employees
- 7
- Website
- aminextx.com/
- Ownership
- Privately Held (backing)
Aminex Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aminex Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aminex Therapeutics in its N-PORT filings yet. We sweep new filings monthly.